We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




bioMérieux Acquires Microbial Genotyping Technology

By Labmedica staff writers
Posted on 03 Oct 2006
bioMérieux (Marcy-l'Etoile, France), a company specializing in in vitro diagnostics, has acquired Bacterial Barcodes (BBCI, Athens, Georgia, USA). More...
The financial terms of the acquisition were not disclosed.

BBCI is a molecular biotechnology company that developed and markets DiversiLab, a system dedicated to the field of automated microbial genotyping, offering solutions to track hospital-acquired infections (HAI) and for environmental control for product safety.

The technology automates the previously cumbersome method of strain typing and allows for better genotypic characterization of bacteria, yeast, and fungi, which helps identify the source and stop the spread of further infection. DiversiLab complements the bioMérieux suite of solutions, and together they support clinical decisions that may ultimately reduce HAIs and support the prudent usage of antibiotics.

The DiversiLab system eliminates complex manual laboratory procedures for determining the source of infections and contamination. DiversiLab allows healthcare practitioners and quality control/assurance departments to conduct investigations up to 10 times faster than previous methods. The system consists of web-based software for detection and analysis, and quality-controlled DNA fingerprinting kits (or reagents).

The technology is focused on the rapid identification of outbreak and contamination source tracking and is applicable in the hygiene market for tracking antibiotic resistant microorganisms causing hospital-acquired infections and in industrial markets for food, agricultural, pharmaceutical, and environmental contamination testing. It is also useful for characterizing biothreat agents and identifying potential outbreaks in the biodefense market.

"We are excited about the opportunity to join the industry leader in the field of infectious disease diagnostics and infection control and we feel positive about the impact our solutions can have in both the healthcare and industrial markets,” said Mimi Healy, Ph.D., president and CEO, BBCI. "The DiversiLab system perfectly complements bioMerieux's technology portfolio, which will help discriminate and track the spread and source of bacterial infections and contamination more quickly, more accurately, and more cost-effectively than other systems on the market today.”



Related Links:
bioMérieux
Bacterial Barcodes

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.